Marrow fibrosis is an independent predictor of hematological toxicity of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia

References

• Sawyers CL. Chronic myeloid leukemia. N Engl J Med. 1999;340(17):1330–1340.
   PubMed Web of Science ®Google Scholar
• Kalmanti L, Saussele S, Lauseker M, et al. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. Leukemia. 2015;29(5):1123–1132.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kim DW, Pinilla-Ibarz J, et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018;132(4):393–404.
   PubMed Web of Science ®Google Scholar
• Jain P, Kantarjian H, Jabbour E, et al. Ponatinib as first-line treatment for patients with chronic myeloid leukemia in chronic phase: a phase 2 study. Lancet Haematol. 2015;2(9):e376–383.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Giles FJ, Bhalla KN, et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood. 2011;117(4):1141–1145.
   PubMed Web of Science ®Google Scholar
• Shah NP, Kim DW, Kantarjian H, et al. Potent transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica. 2010;95(2):232–240.
   Google Scholar
• Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34(20):2333–2340.
   PubMed Web of Science ®Google Scholar
• Thiele J, Kvasnicka HM, Facchetti F, et al. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90(8):1128–1132.
   PubMed Web of Science ®Google Scholar
• Baccarani M, Deininger MW, Rosti G, et al. European Leukemia Net recommendations for the management of chronic myeloid leukemia:2013. Blood. 2013;122(6):872–884.
   PubMed Web of Science ®Google Scholar
• Rosti G, Iacobucci I, Bassi S, et al. Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party. Haematologica. 2007;92(1):101–105.
   PubMed Web of Science ®Google Scholar
• Latagliata R, Breccia M, Carmosino I, et al. Real-life results of front-line treatment with Imatinib in older patients (≥65 years) with newly diagnosed chronic myelogenous leukemia. Leuk Res. 2010;34(11):1472–1475.
   PubMed Web of Science ®Google Scholar
• Deininger MWN, O’Brien SG, Ford JM, et al. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol. 2003;21(8):1637–1647.
   PubMed Web of Science ®Google Scholar
• Breccia M, Stefanizzi C, Cannella L, et al. Differences in hematological and non-Hematological toxicity during treatment with imatinib in patients with early and late chronic phase chronic myeloid leukemia. Leuk Lymphoma. 2008;49(12):2328–2332.
   PubMed Web of Science ®Google Scholar
• Buesche G, Hehlmann R, Hecker H, et al. Marrow fibrosis, indicator of therapy failure in chronic myeloid leukemia-prospective long-term results from a randomized-controlled trial. Leukemia. 2003;17(12):2444–2453.
   PubMed Web of Science ®Google Scholar
• Dekmezian R, Kantarjian HM, Keating MJ, et al. The relevance of reticulin stain-measured fibrosis at diagnosis in chronic myelogenous leukemia. Cancer. 1987;59(10):1739–1743.
   PubMed Web of Science ®Google Scholar
• Tanrikulu Simsek E, Eskazan AE, Cengiz M, et al. Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia. J Clin Pathol. 2016;69(9):810–816.
   PubMed Web of Science ®Google Scholar
• Rajantie J, Sale GE, Deeg HJ, et al. Adverse effect of severe marrow fibrosis on hematologic recovery after chemoradiotherapy and allogeneic bone-marrow transplantation. Blood. 1986;67(6):1693–1697.
   PubMed Web of Science ®Google Scholar
• Giles FJ, Rea D, Rosti G, et al. Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis. J Cancer Res Clin Oncol. 2017;143(8):1585–1596.
   PubMed Web of Science ®Google Scholar
• Ota S, Matsukawa T, Yamamoto S, et al. Severe adverse events by tyrosine kinase inhibitors decrease survival rates in patients with newly diagnosed chronic- phase chronic myeloid leukemia. Eur J Haematol. 2018;101(1):95–105.
   PubMed Web of Science ®Google Scholar
• Marin D, Bazeos A, Mahon FX, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28(14):2381–2388.
   PubMed Web of Science ®Google Scholar
• Ibrahim AR, Eliasson L, Apperley JF, et al. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood. 2011;117(14):3733–3736.
   PubMed Web of Science ®Google Scholar
• Beham-Schmid C, Apfelbeck U, Sill H, et al. Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis. Blood. 2002;99(1):381–383.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Bueso-Ramos CE, Talpaz M, et al. The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy. Leuk Lymphoma. 2005;46(7):993–997.
   PubMed Web of Science ®Google Scholar
• Buesche G, Ganser A, Schlegelberger B, et al. Marrow fibrosis and its relevance during imatinib treatment of chronic myeloid leukemia. Leukemia. 2007;21(12):2420–2427.
   PubMed Web of Science ®Google Scholar
• Eliacik E, Isik A, Aydin C, et al. Bone marrow fibrosis may be an effective independent predictor of the 'TKI drug response level' in chronic myeloid leukemia. Hematology. 2015;20(7):392–396.
   PubMed Web of Science ®Google Scholar